<rss version="2.0">
<channel>
<title>IBTimes.com RSS Feed - Vytorin</title>
<description>International Business News - Vytorin</description>
<link>http://www.ibtimes.com</link>
<copyright>All articles are copyrighted by IBTimes.com</copyright>

<image>
	<title>The International Business Times - Business News, Updated daily</title> 
	<width>400</width> 
	<height>100</height> 
	<link>http://www.ibtimes.com/</link> 
	<url>http://www.ibtimes.com/images/top_logo_ibt2_3.gif</url> 
</image>


  <item>
  <title>House committee widens probe of Vytorin safety</title>
  <description>A House committee investigating the safety and effectiveness of the popular cholesterol drug Vytorin and one of its components is turning up the heat on the drug's makers.</description>
    <link>http://www.ibtimes.com/articles/20080904/house-committee-widens-probe-of-vytorin-safety.htm</link> 
  <pubDate>Thu, 04 Sep 2008 19:47:58 EDT</pubDate>
  </item>


  <item>
  <title>Docs' caution hurts Merck, Schering-Plough shares</title>
  <description>Shares of partner drugmakers Merck &amp; Co. and Schering-Plough Corp. fell Tuesday after experts, reacting to new findings on a possible cancer link to the companies' cholesterol fighter Vytorin, essentially urged patients to avoid the drug if possible.</description>
    <link>http://www.ibtimes.com/articles/20080902/docs-caution-hurts-merck-schering-plough-shares.htm</link> 
  <pubDate>Tue, 02 Sep 2008 17:09:59 EDT</pubDate>
  </item>


  <item>
  <title>Summary Box: The Vytorin question</title>
  <description>CHOLESTEROL COUNT: Three studies of the cholesterol-lowering drug Vytorin, funded by its makers, can't prove or rule out a possible link to a higher risk of cancer that emerged this summer.</description>
    <link>http://www.ibtimes.com/articles/20080902/summary-box-the-vytorin-question.htm</link> 
  <pubDate>Tue, 02 Sep 2008 15:58:09 EDT</pubDate>
  </item>


  <item>
  <title>Doctors say Vytorin-cancer link can't be ruled out</title>
  <description>Results so far from three studies of the cholesterol-lowering drug Vytorin are not enough to prove or rule out a possible link to a higher risk of cancer, so the drug should be used with caution until more is known, editors of a leading medical journal urged Tuesday.</description>
    <link>http://www.ibtimes.com/articles/20080902/study-no-proof-of-vytorin-link-to-cancer.htm</link> 
  <pubDate>Tue, 02 Sep 2008 11:43:32 EDT</pubDate>
  </item>


  <item>
  <title>FDA investigates possible Vytorin link to cancer</title>
  <description>Federal drug safety regulators said Thursday they are investigating whether the cholesterol-lowering drug Vytorin can increase patients' risk of developing cancer.</description>
    <link>http://www.ibtimes.com/articles/20080821/fda-investigates-possible-vytorin-link-to-cancer.htm</link> 
  <pubDate>Thu, 21 Aug 2008 16:28:36 EDT</pubDate>
  </item>


  <item>
  <title>FDA investigates possible Vytorin link to cancer</title>
  <description>Federal drug safety regulators said Thursday they are investigating whether the cholesterol-lowering drug Vytorin can increase patients' risk of developing cancer.</description>
    <image>
  <url>http://www.ibtimes.com/data/articleimgs/113613-vytorin-cancer-risk.jpg</url>
  <link>http://www.ibtimes.com/articles/20080821/lawmakers-demand-study-data-on-vytorin-cancer-risk.htm</link>
  </image>
    <link>http://www.ibtimes.com/articles/20080821/lawmakers-demand-study-data-on-vytorin-cancer-risk.htm</link> 
  <pubDate>Thu, 21 Aug 2008 18:54:50 EDT</pubDate>
  </item>


  <item>
  <title>Merck and Schering-Plough prepare Vytorin letter</title>
  <description>Vytorin partners Merck &amp; Co. and Schering-Plough Corp. have prepared a letter for physicians who might be concerned over recent study results that showed patients taking the cholesterol drug were at higher risk of dying from cancer.</description>
    <link>http://www.ibtimes.com/articles/20080723/merck-and-schering-plough-prepare-vytorin-letter.htm</link> 
  <pubDate>Wed, 23 Jul 2008 16:29:22 EDT</pubDate>
  </item>


  <item>
  <title>Schering-Plough, Merck's Vytorin misses study goal</title>
  <description>In the latest disappointment over cholesterol pill Vytorin, a major European study in patients with heart valve disease found the drug didn't prevent worsening of the disease or lower the need for valve surgery. Its makers' shares plunged about 15 percent.</description>
    <image>
  <url>http://www.ibtimes.com/data/articleimgs/94980-schering-plough-merck-delay.jpg</url>
  <link>http://www.ibtimes.com/articles/20080721/schering-plough-mercks-vytorin-misses-main-goal.htm</link>
  </image>
    <link>http://www.ibtimes.com/articles/20080721/schering-plough-mercks-vytorin-misses-main-goal.htm</link> 
  <pubDate>Mon, 21 Jul 2008 19:34:45 EDT</pubDate>
  </item>


</channel>
</rss>